Ticker Symbol: ANVS
Annovis Bio Inc
$28.58 - 20-12-2024 4 p.m. ET
Exchange: NEW YORK STOCK EXCHANGE INC.
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001477845
Company Profile
annovis bio, inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. its lead compound is anvs401, which is in phase 2a clinical trials for the treatment of alzheimer's disease (ad), parkinson's disease, alzheimer's disease in down syndrome, and other chronic neurodegenerative disorders. the company is also developing anvs405 for protecting the brain after traumatic brain injury and/or stroke; and anvs301, which is in phase i clinical trials to increase cognitive capability in later stages of ad and dementia. annovis bio, inc. was founded in 2008 and is based in berwyn, pennsylvania.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 1055 Westlakes Dr Ste 300
Website: https://www.annovisbio.com/
CEO: Maria Maccecchini
Tags:
- Electronic Equipment/Instruments
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $8.58
Change:
-$0.62
(
-6.74%)
Days Range: $8.44 - $9.00
Beta: 0.75
52wk. High: $23.89
52wk. Low: $7.40
Ytd. Change -42.85%
50 Day Moving Average: $9.69
200 Day Moving Average: $12.76
Shares Outstanding: 9012273
Valuation
Market Cap: 7.7B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A